Image provided by OnJourney
OnJourney (CEO Sang Hun Lee) is a digital healthcare and medical device company established in January 2021, with the mission of “ensuring a beautiful and healthy life throughout an extended lifespan.”
OnJourney develops next-generation diabetes management solutions that go beyond simple data recording, integrating an AI-based prediction and coaching platform with glucose measurement and drug delivery technologies in response to the rapid rise in chronic diseases such as diabetes and obesity.
The company is growing into a global provider of diabetes management solutions by unifying its own edge AI–powered continuous glucose monitor (CGM), AI-based glucose management and prediction platform, and insulin drug delivery devices into a single ecosystem.
OnJourney’s business targets consumers with chronic conditions, including diabetes and obesity, as well as B2B partners such as hospitals, clinics, medical professionals, and pharmaceutical and biotech companies. Patients requiring insulin or GLP-1 injections, as well as children and older adults who need more precise and convenient management, are its core user base. The company also views partnerships with insurers and healthcare platform operators as central pillars of its business, and it is accelerating global expansion in the United States, Southeast Asia, and the Middle East.
To address the growing global burden of chronic diseases such as diabetes and obesity, OnJourney develops next-generation diabetes management solutions that integrate AI platforms, continuous glucose monitors, and drug delivery devices. Its AI coaching platform PICKEAT provides personalized management by predicting and recommending diet, exercise, and dosage based on glucose data. Users can easily understand their glucose patterns and lifestyle habits and manage daily health more scientifically and sustainably.
The PICKPEN drug injection pen, equipped with a hidden needle and precision extrusion technology, is a medical device designed to minimize fear and pain while allowing accurate and consistent dosing. Along with this, a prefilled pen and a needle-free injector called Injectra expand the drug delivery lineup, offering convenience and accuracy for patients who must repeatedly administer high-viscosity medications. With sensors, pens, injectors, and other devices, patients can choose the most suitable delivery method for their condition and prescription.
Image provided by OnJourney
In the CGM field, OnJourney is developing a next-generation continuous glucose monitor equipped with enzyme-free catalysts and bipolar electrode(BPE) technology. The device aims for industry-leading performance, with high accuracy (MARD 7%) and a short lag time of 5–10 minutes. It applies edge AI to analyze measurement data in real time. It aims to achieve price competitiveness so CGM can be used at a monthly cost of around 50,000 KRW, rather than being perceived as high-end equipment.
These technologies and products were developed to address recurring pain points in the market, including difficulties with self-management, limitations in sensor accuracy and lifespan, fear of injections, and challenges with precise dosing. OnJourney is preparing for global expansion by realizing a fully connected, one-stop system—Seamless Diabetic Management System—that integrates measurement, prediction, and delivery.
As a diabetes-specialized medical device company, OnJourney considers entry into the United States—the world’s largest healthcare market—its top priority. In the CGM device sector, starting with CES 2026, the company sees Abbott, Medtronic, and Dexcom as its primary negotiation targets and is exploring collaboration models with them. In the drug delivery solutions sector, amid global attention to GLP-1 medications, the company targets Eli Lilly, Roche, and Wegovy-related partners in the United States. For automated insulin patches, Insulet and Medtronic are mentioned as potential collaborators and buyers.
OnJourney has so far secured about 1 billion KRW in cumulative investment to develop core technologies and is currently conducting its pre-Series A round. The company achieved 1.83 billion KRW in revenue in 2024, reaching breakeven, and is pursuing a growth strategy to achieve 5 billion KRW in revenue in 2025. It launched the diabetes AI coaching platform PICKEAT in 2024 and introduced the blood-sugar-spiking–reducing post-meal glucose-control film MOODANGTEA in March 2025. In May 2025, after obtaining regulatory approval for medical device manufacturing from the Ministry of Food and Drug Safety, it began full-scale sales of PICKPEN, featuring an invisible-needle structure with a 34G micro-pain needle.
The invasive CGM under development was selected for the Gyeonggi-do Business & Science Accelerator medical device support program, and the company is completing its bipolar MCU and undergoing performance evaluation. Based on this technology, OnJourney plans to begin clinical trials at Bundang CHA Hospital and Pohang Semyeong Christian Hospital in 2026, after which it aims to accelerate global market entry.
OnJourney plans to continue evolving its end-to-end diabetes management solution by integrating AI, sensors, and drug delivery devices, becoming a global healthcare company that delivers new value to patients, medical professionals, and pharmaceutical and biotech companies.
